The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).
 
Ferdinandos Skoulidis
Stock and Other Ownership Interests - BioNTech; Moderna Therapeutics
Honoraria - ESMO; McGill Universite de Montreal; RV Mais
Consulting or Advisory Role - Amgen; BeiGene; Calithera Biosciences; Intellisphere; Medscape; Navire; Tango Therapeutics
Research Funding - AIMM Therapeutics (I); Amgen (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
 
Mary Weber Redman
No Relationships to Disclose
 
Jennifer Marie Suga
No Relationships to Disclose
 
Tareq Al Baghdadi
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Epizyme; HERON; Spectrum Pharmaceuticals; Sunesis Pharmaceuticals
Honoraria - Cardinal Health
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; Karyopharm Therapeutics; MorphoSys
 
John L. Villano
No Relationships to Disclose
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Janssen; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Liza C Villaruz
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; Jazz Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); BMS (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Rain Therapeutics (Inst); Regeneron (Inst)
 
Katherine Minichiello
No Relationships to Disclose
 
David R. Gandara
Honoraria - Amgen; Merck
Consulting or Advisory Role - Adagene (Inst); AstraZeneca (Inst); Daiichi Sankyo Alliance; Guardant Health (Inst); Guardant Health (Inst); IO Biotech (Inst); Lilly; Novartis; Ocean Genomics (Inst); OncoCyte (Inst); OncoHost (Inst); Roche/Genentech (Inst); Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Merck (Inst)
 
Roy S. Herbst
Leadership - Immunocore; Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Bayer; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Foundation Medicine; Genentech/Roche; Genmab; Gilead/Forty Seven; Halozyme; Heat Biologics; HiberCell; I-Mab; Immune-Onc Therapeutics; Infinity Pharmaceuticals; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Ribon Therapeutics; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; STCube Pharmaceuticals Inc.; Symphogen; Takeda; TESARO; Tocagen; Ventana Medical Systems; WindMIL; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sanko; Debiopharm Group; Eisai; EMD Serono; Genentech; Genmab; Janssen; Lilly; Novartis; Regeneron; Sanofi; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Meyers Squibb (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - EMD Serono; Lilly; Novartis; Takeda